PUBLISHER: Grand View Research | PRODUCT CODE: 1404770
PUBLISHER: Grand View Research | PRODUCT CODE: 1404770
The global in vitro fertilization market size is expected to reach USD 37.4 billion by 2030, with a CAGR of 5.54% from 2024 to 2030, based on a new report by Grand View Research, Inc.The market's growth can be attributed to the continuous efforts of the market players, an increase in the incidence of infertility due to lifestyle changes, and government initiatives to improve reimbursement policies. Expansion of fertility procedures, such as Intracytoplasmic sperm injection (ICSI) for treating infertility, is expected to have a positive impact on market growth.
The availability of genomic testing facilities that enable the prevention of the transfer of genetic disorders during in vitro fertilization (IVF) is expected to drive the IVF market. The insurance providers are providing coverage for IVF procedures owing to an increase in the number of IVF treatments. For instance, in May 2023, Pacific Blue Cross introduced an enhanced Personal Health Insurance, a health & dental plan, which incorporates family planning benefits, including coverage for fertility drugs, fertility treatments, and adoption. With this enhancement, Pacific Blue Cross became the first and only provider in Canada to offer family planning benefits as part of an individual health & dental plan. This led to competitive pricing and moderated IVF treatment costs. This procedure has been a successfully practiced technology, driving the market with more treatment automation and standardization.
A decline in the Total Fertility Rate (TFR) results from factors, such as behavioral shifts in society. These factors include a shift from rural to urban societies, increased age of the first pregnancy, postponement of marriage, increased employment, and lower marriage rates. In March 2020, in-person fertility treatments in the U.S. and Canada were suspended due to COVID-19 by the American Society of Reproductive Medicine and Canadian Fertility and Andrology Society. However, treatment is resumed in many countries with the ease of COVID-19 restrictions. The research findings published by the Obstetrics & Gynecology journal in January 2022 reported that COVID-19 vaccines wouldn't harm IVF outcomes. This is expected to prove the uptake of IVF in eligible vaccinated individuals.